(Reuters) – The U.S. Food and Drug Administration (FDA) approved a nasal spray from Pfizer (PFE.N) for migraines on March 10.
Zavzpret has been approved for the treatment of acute migraines, the company said. Pfizer acquired the drug and the FDA-approved oral migraine drug Nurtec ODT through its $11.6 billion acquisition of Biohaven Pharmaceuticals last year.
Pfizer expects peak sales for its migraine pipeline to be approximately $6 billion.
Zavzpret, which goes on sale in July, will be priced on par with other FDA-approved migraine drugs in the same class of drugs, Pfizer told Reuters.
The drug, also known as zavegepant, is a rival to AbbVie, Eli Lilly & Co. (LLY.N), Amgen (AMGN.O) and Teva Pharmaceuticals (TEVA.TA), also a calcitonin gene-related peptide. will compete. (CGRP) inhibitor.
latest update
Show 2 more stories
Dr. Emad Estemalik, a psychiatrist at the Cleveland Clinic, said, “[Pfizer’s]drug has two main advantages over older CGRP antagonists.
Nasal sprays can also benefit patients who can’t swallow pills, says Estemalik.
Pfizer hopes to gain a competitive edge in the migraine drug category with Zabzpret, which Biohaven called a “migraine epipen.”
Zavzpret’s approval was based on late-stage trial data showing that the drug was superior to placebo in 13 of 17 targets, providing pain relief in 15 minutes and normal function in 30 minutes. was given.
According to the Migraine Research Foundation, approximately 39 million people in the United States suffer from migraines.
Pfizer shares rose slightly to $39.75 in midday trading.
Reported by Khushi Mandowara and Bhanvi Satija of Bangalore. Edited by Anil D’Silva, Vinay Dwivedi and Shinjini Ganguli
Our criteria: Thomson Reuters Trust Principles.
